2-hydrazinyl-6-methoxy-4-(trifluoromethyl)pyridine | 261360-23-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-hydrazinyl-6-methoxy-4-(trifluoromethyl)pyridine
• 英文别名: 4-trifluoromethyl-6-methoxy-pyridin-2-ylhydrazine；4-trifluoromethyl-6-methoxy-2-pyridylhydrazine；[6-methoxy-4-(trifluoromethyl)pyridin-2-yl]hydrazine
• CAS: 261360-23-0
• 化学式: C₇H₈F₃N₃O
• 分子量: 207.155
• InChiKey: AQROSQLVCDEERB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  60.2
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-hydrazinyl-6-methoxy-4-(trifluoromethyl)pyridine 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 二乙二醇 为溶剂， 反应 8.17h， 生成 6-methoxy-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  [EN] DISUBSTITUTED HETEROARYL-FUSED PYRIDINES
  [FR] PYRIDINES ACCOLÉES À DI-SUBSTITUTION HÉTÉROARYLE

  摘要：

  这项发明涉及公式(I')的化合物，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其作为药物的用途以及包含它的药物。

  公开号：

  WO2011076744A1

文献信息

• [EN] DISUBSTITUTED HETEROARYL-FUSED PYRIDINES<br/>[FR] PYRIDINES ACCOLÉES À DI-SUBSTITUTION HÉTÉROARYLE
  申请人：NOVARTIS AG

  公开号：WO2011076744A1

  公开（公告）日：2011-06-30

  The invention relates to compound of the formula (I') in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  这项发明涉及公式(I')的化合物，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其作为药物的用途以及包含它的药物。
• Medical composition containing nitroetheneamine derivative or salt thereof as active constituent
  申请人：Ishihara Sangyo Kaisha Ltd.

  公开号：US06451792B1

  公开（公告）日：2002-09-17

  A medical composition containing, as an active constituent, a nitroetheneamine derivative represented by the formula (I): wherein the substituents are as defined in the disclosure, its stereoisomers, its tautomers or a salt thereof.

  一种医用组合物，其有效成分为一种由式(I)所表示的硝基乙烯胺衍生物，其中取代基如在本文中所定义，其立体异构体，其互变异构体或其盐。
• Medical composition containing nitroetheneamine Derivative or salt there of as active constituent
  申请人：Ishihara Sangyo Kaisha, Ltd.

  公开号：US06596863B2

  公开（公告）日：2003-07-22

  Process for producing a nitroetheneamine derivative or its stereoisomer, its tautomer or a salt thereof comprising reacting a compound of the formula with a compound of the formula R6—CH2NO2 to obtain a compound of the formula and reacting the resulting compound with a compound of the formula

  生产硝基乙烯胺衍生物或其立体异构体、互变异构体或其盐的过程包括将化合物式的化合物与化合物式的化合物反应，以获得化合物式的化合物，然后将所得化合物与化合物式的化合物反应。
• Disubstituted heteroaryl-fused pyridines
  申请人：Badiger Sangamesh

  公开号：US08742106B2

  公开（公告）日：2014-06-03

  The invention relates to compound of the formula (I′) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  本发明涉及公式（I'）的化合物，其中取代基如规范中所定义；以自由形式或盐形式存在；涉及其制备，用作药物及包含它的药物。
• MEDICAL COMPOSITION CONTAINING NITROETHENEAMINE DERIVATIVE OR SALT THEREOF AS ACTIVE CONSTITUENT
  申请人：ISHIHARA SANGYO KAISHA, LTD.

  公开号：EP1116486A1

  公开（公告）日：2001-07-18

  The present invention provides a medical composition containing, as an active constituent, a nitroetheneamine derivative represented by the formula (I): wherein R1 is hydrogen, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, or cyano; each of R2 and R3 is hydrogen, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, or -A-R7 (A is S, SO, SO2, SO3, CO or CO2, and R7 is hydrogen, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group) ; or R2 and R3 may form N=CR8R9 (each of R8 and R9 is hydrogen, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, alkoxy or aryloxy group, cyano, nitro, or -A-R7 (A and R7 are as defined above); each of R4 and R5 is hydrogen, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, alkoxy, amino or aryloxy group, -A-R7 (A and R7 are as defined above), cyano, ester, or a hydroxyl group; or R4 and R5 may form N=CR8R9 (R8 and R9 are as defined above); R6 is hydrogen, nitro, cyano, -A-R7 (A and R7 are as defined above), an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, alkoxy or amino group, or halogen; and further R1, R2, R3, R4 and R5 may form a ring containing or not containing a hetero atom; or a salt thereof.

  本发明提供了一种医疗组合物，其活性成分含有由式(I)表示的硝基乙烯胺衍生物： 其中 R1 是氢、任选取代的烷基、烯基、炔基、环烷基、环烯基、芳基或杂环基团或氰基；R2 和 R3 各为氢、任选取代的烷基、烯基、炔基、环烷基、环烯基、芳基或杂环基团，或 -A-R7 （A 为 S、SO、SO2、SO3、CO 或 CO2，R7 为氢或任选取代的烷基、烯基、炔基、环烷基、环烯基、芳基或杂环基团）；或 R2 和 R3 可形成 N=CR8R9 （R8 和 R9 各为氢、任选取代的烷基、烯基、炔基、环烷基、环烯基、芳基、杂环基、烷氧基或芳氧基、氰基、硝基或-A-R7（A 和 R7 如上定义）；R4 和 R5 各自为氢、任选取代的烷基、烯基、炔基、环烷基、环烯基、芳基、杂环基、烷氧基、氨基或芳氧基、-A-R7（A 和 R7 如上定义）、氰基、酯或羟基；或 R4 和 R5 可形成 N=CR8R9 （R8 和 R9 如上定义）；R6 是氢、硝基、氰基、-A-R7（A 和 R7 如上定义）、任选取代的烷基、烯基、炔基、环烷基、环烯基、芳基、杂环基、烷氧基或氨基，或卤素；此外，R1、R2、R3、R4 和 R5 可形成含有或不含有杂原子的环；或其盐。